These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 9079238)
1. Effect of the anticholinergic drug with calcium antagonistic activity, (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate, on lower urinary tract function in decerebrated dogs. Kimura Y; Fukui H; Hamada K; Ogasawara T; Yamazaki C; Ukai Y; Yoshikuni Y; Kimura K Arzneimittelforschung; 1997 Feb; 47(2):182-9. PubMed ID: 9079238 [TBL] [Abstract][Full Text] [Related]
2. Effect of the anticholinergic drug with calcium antagonistic activity, (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate, on lower urinary tract function in rhesus monkeys. Kimura Y; Hamada K; Fukui H; Ogasawara T; Ukai Y; Yoshikuni Y; Kimura K Arzneimittelforschung; 1997 Feb; 47(2):189-94. PubMed ID: 9079239 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate. 3rd communication: plasma concentrations of the unchanged drug and its deethylated metabolite in rats, dogs and monkeys. Nakamura A; Hirota T; Sugihara K; Morino A Arzneimittelforschung; 1997 Feb; 47(2):169-74. PubMed ID: 9079236 [TBL] [Abstract][Full Text] [Related]
4. [A comparative study of the effects of propiverine, terodiline, oxybutynin on the lower urinary tract function in the decerebrate dog]. Tsuchida S; Nishizawa O; Noto H; Kaneko S Hinyokika Kiyo; 1990 Aug; 36(8):915-9. PubMed ID: 2239592 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate. 4th communication: metabolism in rats and dogs. Hirota T; Nakamura A; Sugihara K; Morino A Arzneimittelforschung; 1997 Feb; 47(2):175-81. PubMed ID: 9079237 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate. 1st communication: absorption, distribution and excretion after single administration of 14C-labeled compound to rats and dogs. Nakamura A; Sugihara K; Hirota T; Morino A; Ezumi Y; Takaichi M Arzneimittelforschung; 1997 Feb; 47(2):151-9. PubMed ID: 9079234 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of NS-21 and terodiline on the QTc interval in dogs. Natsukawa T; Matsuzaki T; Hayashi S; Ukai Y; Yoshikuni Y; Kimura K Gen Pharmacol; 1998 Jan; 30(1):137-42. PubMed ID: 9457495 [TBL] [Abstract][Full Text] [Related]
8. [Oral single-dose and 13-week repeat-dose toxicity studies of RCC-36, the active metabolite of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate(NS-21), a novel drug for urinary frequency and incontinence, in rats]. Furukawa S; Kouyama H; Kikumori M; Taniguchi Y; Nishimori T; Ishibashi S; Iwakura K; Sumi N J Toxicol Sci; 1997 Apr; 22 Suppl 1():93-124. PubMed ID: 9170604 [TBL] [Abstract][Full Text] [Related]
10. Effect of NS-21, an anticholinergic drug with calcium antagonistic activity, on lower urinary tract function in a rat model of urinary frequency. Sasaki Y; Hamada K; Yamazaki C; Seto T; Kimura Y; Ukai Y; Yoshikuni Y; Kimura K Int J Urol; 1997 Jul; 4(4):401-6. PubMed ID: 9256331 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate. 2nd communication: tissue levels and enzyme activity in rats after repeated administration, and placental and milk transfer after single administration. Nakamura A; Hirota T; Sugihara K; Watanabe S; Tougou K; Morino A; Ezumi Y; Takaichi M Arzneimittelforschung; 1997 Feb; 47(2):160-8. PubMed ID: 9079235 [TBL] [Abstract][Full Text] [Related]
12. [Toxicokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in mice and rats during 13-week dietary administration]. Nakazawa M; Kitayama E; Adachi T; Yoshida M; Ishibashi S; Yoshikawa K; Kajihara T; Iwakura K; Sumi N J Toxicol Sci; 1997 Apr; 22 Suppl 1():177-85. PubMed ID: 9170607 [TBL] [Abstract][Full Text] [Related]
14. [Mutagenicity studies of RCC-36, the active metabolite of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence]. Tamura H; Yamashita Y; Kitayama E; Iwakura K; Watanabe M; Sumi N J Toxicol Sci; 1997 Apr; 22 Suppl 1():263-74. PubMed ID: 9170614 [TBL] [Abstract][Full Text] [Related]
16. [A 12-month oral repeated dose toxicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in dogs followed by a 2-month recovery test]. Yoshida M; Kawaminami A; Tawaratani T; Ishibashi S; Nakazawa M; Kitayama E; Oka T; Adachi T; Iwakura K; Sumi N J Toxicol Sci; 1997 Apr; 22 Suppl 1():147-75. PubMed ID: 9170606 [TBL] [Abstract][Full Text] [Related]
17. [Intraperitoneal single-dose toxicity studies of active metabolite, optical isomers, hydrolysis products and bi-product of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate(NS-21), a novel drug for urinary frequency and incontinence, in mice]. Nishimura N; Kobayashi J; Moro M; Katsumata T; Nishiguchi Y; Iwakura K; Sumi N J Toxicol Sci; 1997 Apr; 22 Suppl 1():15-25. PubMed ID: 9170601 [TBL] [Abstract][Full Text] [Related]
18. [A 26-week oral repeated dose toxicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in rats followed by a 9-week recovery test]. Okasaki K; Baba S; Ikeda H; Chihaya Y; Satake S; Nagata R; Ishibashi S; Iwakura K; Sumi N J Toxicol Sci; 1997 Apr; 22 Suppl 1():59-92. PubMed ID: 9170603 [TBL] [Abstract][Full Text] [Related]
19. [A 13-week oral repeated dose toxicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in dogs followed by a 5-week recovery test]. Yoshida M; Oka T; Tawaratani T; Ishibashi S; Nakazawa M; Kitayama E; Adachi T; Iwakura K; Sumi N J Toxicol Sci; 1997 Apr; 22 Suppl 1():125-46. PubMed ID: 9170605 [TBL] [Abstract][Full Text] [Related]
20. [The mechanism of increased thyroidal function caused by (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate(NS-21), a novel drug for urinary frequency and incontinence, administration in rats]. Ishibashi S; Nakazawa M; Tawaratani T; Yoshida M; Tamura H; Adachi T; Kawaguchi K; Iwakura K; Sumi N; Wakabayashi K J Toxicol Sci; 1997 Apr; 22 Suppl 1():187-99. PubMed ID: 9170608 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]